Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges

Fire, 1998, Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature, 391, 806, 10.1038/35888

Zamore, 2000, RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals, Cell, 101, 25, 10.1016/S0092-8674(00)80620-0

Elbashir, 2001, Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells, Nature, 411, 494, 10.1038/35078107

Davidson, 2011, Current prospects for RNA interference-based therapies, Nat. Rev. Genet., 12, 329, 10.1038/nrg2968

Burnett, 2012, RNA-based therapeutics: current progress and future prospects, Chem. Biol., 19, 60, 10.1016/j.chembiol.2011.12.008

Lares, 2010, RNAi and small interfering RNAs in human disease therapeutic applications, Trends Biotechnol., 28, 570, 10.1016/j.tibtech.2010.07.009

Dejneka, 2008, Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes, Mol. Vis., 14, 997

Cho, 2009, Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth, Proc. Natl. Acad. Sci. U. S. A., 106, 7137, 10.1073/pnas.0812317106

Kleinman, 2008, Sequence- and target-independent angiogenesis suppression by siRNA via TLR3, Nature, 452, 591, 10.1038/nature06765

Whitehead, 2009, Knocking down barriers: advances in siRNA delivery, Nat. Rev. Drug Discov., 8, 129, 10.1038/nrd2742

Dominska, 2010, Breaking down the barriers: siRNA delivery and endosome escape, J. Cell Sci., 123, 1183, 10.1242/jcs.066399

Wang, 2008, Nanotechnology and aptamers: applications in drug delivery, Trends Biotechnol., 26, 442, 10.1016/j.tibtech.2008.04.006

Kim, 2009, Engineered polymers for advanced drug delivery, Eur. J. Pharm. Biopharm., 71, 420, 10.1016/j.ejpb.2008.09.021

Guo, 2012, Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology, Nucleic Acid Ther., 22, 226, 10.1089/nat.2012.0350

Shen, 2012, Nanovector delivery of siRNA for cancer therapy, Cancer Gene Ther., 19, 367, 10.1038/cgt.2012.22

Lee, D.U., Huang, W., Rittenhouse, K.D., and Jessen, B. (2012). Retina Expression and Cross-Species Validation of Gene Silencing by PF-655, a Small Interfering RNA Against RTP801 for the Treatment of Ocular Disease. J. Ocul. Pharmacol. Ther.

Sarret, 2010, Direct application of siRNA for in vivo pain research, Methods Mol. Biol., 623, 383, 10.1007/978-1-60761-588-0_25

Barik, 2011, Intranasal delivery of antiviral siRNA, Methods Mol. Biol., 721, 333, 10.1007/978-1-61779-037-9_20

DeVincenzo, 2010, A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus, Proc. Natl. Acad. Sci. US A, 107, 8800, 10.1073/pnas.0912186107

Juliano, 2008, Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides, Nucleic Acids Res., 36, 4158, 10.1093/nar/gkn342

Guerra, 2011, Barriers to non-viral vector-mediated gene delivery in the nervous system, Pharm. Res., 28, 1843, 10.1007/s11095-010-0364-7

Boerman, 2006, Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules, Drug Metab. Dispos., 34, 1393, 10.1124/dmd.106.009555

Wang, 2010, Delivery of siRNA therapeutics: barriers and carriers, Aaps. J., 12, 492, 10.1208/s12248-010-9210-4

Danquah, 2011, Extravasation of polymeric nanomedicines across tumor vasculature, Adv. Drug Deliv. Rev., 63, 623, 10.1016/j.addr.2010.11.005

Yuan, 1995, Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size, Cancer Res., 55, 3752

Moghimi, 2001, Long-circulating and target-specific nanoparticles: theory to practice, Pharmacol. Rev., 53, 283

Matsumura, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res., 46, 6387

Greish, 2007, Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines, J. Drug Target., 15, 457, 10.1080/10611860701539584

Jain, 1987, Transport of molecules in the tumor interstitium: a review, Cancer Res., 47, 3039

Boucher, 1990, Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy, Cancer Res., 50, 4478

Perrault, 2010, In vivo assembly of nanoparticle components to improve targeted cancer imaging, Proc. Natl. Acad. Sci. USA, 107, 11194, 10.1073/pnas.1001367107

Netti, 2000, Role of extracellular matrix assembly in interstitial transport in solid tumors, Cancer Res., 60, 2497

Wong, 2011, Multistage nanoparticle delivery system for deep penetration into tumor tissue, Proc. Natl. Acad. Sci. USA, 108, 2426, 10.1073/pnas.1018382108

Peer, 2007, Nanocarriers as an emerging platform for cancer therapy, Nat. Nanotechnol., 2, 751, 10.1038/nnano.2007.387

Gullotti, 2009, Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery, Mol. Pharm., 6, 1041, 10.1021/mp900090z

Davis, 2009, The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic, Mol. Pharm., 6, 659, 10.1021/mp900015y

Davis, 2010, Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles, Nature, 464, 1067, 10.1038/nature08956

Schroeder, 2010, Lipid-based nanotherapeutics for siRNA delivery, J. Intern. Med., 267, 9, 10.1111/j.1365-2796.2009.02189.x

Nguyen, 2012, Nucleic acid delivery: the missing pieces of the puzzle?, Acc. Chem. Res., 45, 1153, 10.1021/ar3000162

Mukherjee, 1997, Endocytosis, Physiol. Rev., 77, 759, 10.1152/physrev.1997.77.3.759

Kumari, 2010, Endocytosis unplugged: multiple ways to enter the cell, Cell Res., 20, 256, 10.1038/cr.2010.19

Varkouhi, 2011, Endosomal escape pathways for delivery of biologicals, J. Control. Release, 151, 220, 10.1016/j.jconrel.2010.11.004

Boussif, 1995, A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine, Proc. Natl. Acad. Sci. USA, 92, 7297, 10.1073/pnas.92.16.7297

Cho, 2003, Polycation gene delivery systems: escape from endosomes to cytosol, J. Pharm. Pharmacol., 55, 721, 10.1211/002235703765951311

Turner, 2005, Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells, Nucleic Acids Res., 33, 6837, 10.1093/nar/gki991

Shiraishi, 2005, Calcium ions effectively enhance the effect of antisense peptide nucleic acids conjugated to cationic tat and oligoarginine peptides, Chem. Biol., 12, 923, 10.1016/j.chembiol.2005.06.009

Abes, 2006, Endosome trapping limits the efficiency of splicing correction by PNA-oligolysine conjugates, J. Control. Release, 110, 595, 10.1016/j.jconrel.2005.10.026

Shiraishi, 2006, Photochemically enhanced cellular delivery of cell penetrating peptide-PNA conjugates, FEBS Lett., 580, 1451, 10.1016/j.febslet.2006.01.077

Ohtsuki, 2012, Photoinduced RNA interference, Acc. Chem. Res., 45, 1039, 10.1021/ar200227n

Blidner, 2008, Photoinduced RNA interference using DMNPE-caged 2'-deoxy-2'-fluoro substituted nucleic acids in vitro and in vivo, Mol. Biosyst., 4, 431, 10.1039/b801532e

Endoh, T., Sisido, M., and Ohtsuki, T. (2007). Photo inducible RNA interference using cell permeable protein carrier. Nucleic Acids Symp. Ser. (Oxf.), 127–128.

Endoh, 2008, Cellular siRNA delivery mediated by a cell-permeant RNA-binding protein and photoinduced RNA interference, Bioconjug. Chem., 19, 1017, 10.1021/bc800020n

Endoh, 2009, Spatial regulation of specific gene expression through photoactivation of RNAi, J. Control. Release, 137, 241, 10.1016/j.jconrel.2009.04.015

Braun, 2009, Laser-Activated Gene Silencing via Gold Nanoshell-siRNA Conjugates, ACS Nano, 3, 2007, 10.1021/nn900469q

Hammond, 2001, Argonaute2, a link between genetic and biochemical analyses of RNAi, Science, 293, 1146, 10.1126/science.1064023

Liu, 2004, Argonaute2 is the catalytic engine of mammalian RNAi, Science, 305, 1437, 10.1126/science.1102513

Sakurai, 2011, A role for human Dicer in pre-RISC loading of siRNAs, Nucleic Acids Res., 39, 1510, 10.1093/nar/gkq846

Matranga, 2005, Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes, Cell, 123, 607, 10.1016/j.cell.2005.08.044

Gibbings, 2009, Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity, Nat. Cell Biol., 11, 1143, 10.1038/ncb1929

Lee, 2009, Silencing by small RNAs is linked to endosomal trafficking, Nat. Cell Biol., 11, 1150, 10.1038/ncb1930

Sen, 2005, Argonaute 2/RISC resides in sites of mammalian mRNA decay known as cytoplasmic bodies, Nat. Cell Biol., 7, 633, 10.1038/ncb1265

Rossi, 2005, RNAi and the P-body connection, Nat. Cell Biol., 7, 643, 10.1038/ncb0705-643

Meister, 2004, Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs, Mol. Cell, 15, 185, 10.1016/j.molcel.2004.07.007

Davis, 2008, Nanoparticle therapeutics: an emerging treatment modality for cancer, Nat. Rev. Drug Discov., 7, 771, 10.1038/nrd2614

Petros, 2010, Strategies in the design of nanoparticles for therapeutic applications, Nat. Rev. Drug Discov., 9, 615, 10.1038/nrd2591

Zhang, 2008, Nanoparticles in medicine: therapeutic applications and developments, Clin. Pharmacol. Ther., 83, 761, 10.1038/sj.clpt.6100400

Fonseca, 2012, Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges, Acc. Chem. Res., 45, 1163, 10.1021/ar300048p

Torchilin, 2005, Recent advances with liposomes as pharmaceutical carriers, Nat. Rev. Drug Discov., 4, 145, 10.1038/nrd1632

Proffitt, 2002, AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience, J. Antimicrob. Chemother., 49, 21, 10.1093/jac/49.suppl_1.21

Hoekstra, 2007, Gene delivery by cationic lipids: in and out of an endosome, Biochem. Soc. Trans., 35, 68, 10.1042/BST0350068

Jeong, 2011, Self-assembled and nanostructured siRNA delivery systems, Pharm. Res., 28, 2072, 10.1007/s11095-011-0412-y

Uchida, 2002, Comparison of the efficiency and safety of non-viral vector-mediated gene transfer into a wide range of human cells, Biol. Pharm. Bull., 25, 891, 10.1248/bpb.25.891

Balazs, 2011, Liposomes for use in gene delivery, J. Drug Deliv., 2011, 326497, 10.1155/2011/326497

Schafer, 2010, Liposome-polyethylenimine complexes for enhanced DNA and siRNA delivery, Biomaterials, 31, 6892, 10.1016/j.biomaterials.2010.05.043

Sakurai, 2011, Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA, Biomaterials, 32, 5733, 10.1016/j.biomaterials.2011.04.047

Rossi, 2006, RNAi therapeutics: SNALPing siRNAs in vivo, Gene Ther., 13, 583, 10.1038/sj.gt.3302661

Grefhorst, 2008, Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates, Proc. Natl. Acad. Sci. U. S. A., 105, 11915, 10.1073/pnas.0805434105

Landesman, 2010, In vivo quantification of formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR), Silence, 1, 16, 10.1186/1758-907X-1-16

Aleku, 2008, Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression, Cancer Res., 68, 9788, 10.1158/0008-5472.CAN-08-2428

Strumberg, 2012, Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors, Int. J. Clin. Pharmacol. Ther., 50, 76, 10.5414/CPP50076

Boas, 2004, Dendrimers in drug research, Chem. Soc. Rev., 33, 43, 10.1039/b309043b

Majoros, 2009, Methotrexate delivery via folate targeted dendrimer-based nanotherapeutic platform, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 1, 502, 10.1002/wnan.37

Singha, K., Namgung, R., and Kim, W.J. (2011). Polymers in Small-Interfering RNA Delivery. Oligonucleotides.

Winkler, 2011, Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides, Ther. Deliv., 2, 891, 10.4155/tde.11.56

Ocana, 2012, Dendrimers as vectors for genetic material delivery to the nervous system, Curr. Med. Chem., 19, 5101, 10.2174/0929867311209025101

Kaneshiro, 2009, Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier, Biomaterials, 30, 5660, 10.1016/j.biomaterials.2009.06.026

Shen, 2007, Importance of size-to-charge ratio in construction of stable and uniform nanoscale RNA/dendrimer complexes, Org. Biomol. Chem., 5, 3674, 10.1039/b711242d

Zhou, J., Neff, C.P., Liu, X., Zhang, J., Li, H., Smith, D.D., Swiderski, P., Aboellail, T., Huang, Y., Du, Q., Liang, Z., Peng, L., Akkina, R., and Rossi, J.J. (2011). Systemic Administration of Combinatorial dsiRNAs via Nanoparticles Efficiently Suppresses HIV-1 Infection in Humanized Mice. Mol. Ther., 2228–2238.

Agrawal, 2009, Functional delivery of siRNA in mice using dendriworms, ACS Nano, 3, 2495, 10.1021/nn900201e

Kim, 2008, LHRH receptor-mediated delivery of siRNA using polyelectrolyte complex micelles self-assembled from siRNA-PEG-LHRH conjugate and PEI, Bioconjug. Chem., 19, 2156, 10.1021/bc800249n

Yuan, 2010, Dendrimer-triglycine-EGF nanoparticles for tumor imaging and targeted nucleic acid and drug delivery, Oral Oncol., 46, 698, 10.1016/j.oraloncology.2010.07.001

Pun, 2004, Cyclodextrin-modified polyethylenimine polymers for gene delivery, Bioconjug. Chem., 15, 831, 10.1021/bc049891g

Davis, 2004, Cyclodextrin-based pharmaceutics: past, present and future, Nat. Rev. Drug Discov., 3, 1023, 10.1038/nrd1576

Davis, 2009, Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin, Adv. Drug Deliv. Rev., 61, 1189, 10.1016/j.addr.2009.05.005

Alabi, 2012, Attacking the genome: emerging siRNA nanocarriers from concept to clinic, Curr. Opin. Pharmacol., 12, 427, 10.1016/j.coph.2012.05.004

Kang, 2010, Liver-targeted siRNA delivery by polyethylenimine (PEI)-pullulan carrier, Bioorg. Med. Chem., 18, 3946, 10.1016/j.bmc.2010.04.031

Hobel, 2010, Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab, J. Gene Med., 12, 287, 10.1002/jgm.1431

Schiffelers, 2004, Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle, Nucleic Acids Res., 32, e149, 10.1093/nar/gnh140

Biswal, 2010, Development of a targeted siRNA delivery system using FOL-PEG-PEI conjugate, Mol. Biol. Rep., 37, 2919, 10.1007/s11033-009-9853-3

Nie, 2011, Hepatocyte-targeted psiRNA delivery mediated by galactosylated poly(ethylene glycol)-graft-polyethylenimine in vitro, J. Biomater. Appl., 26, 255, 10.1177/0885328210364678

Moghimi, 2005, A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy, Mol. Ther., 11, 990, 10.1016/j.ymthe.2005.02.010

Li, 2013, A mesoporous silica nanoparticle - PEI - Fusogenic peptide system for siRNA delivery in cancer therapy, Biomaterials, 34, 1391, 10.1016/j.biomaterials.2012.10.072

Hom, 2010, Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells, Small, 6, 1185, 10.1002/smll.200901966

Breccia, 2011, Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy, Expert Opin. Biol. Ther., 11, 225, 10.1517/14712598.2011.543895

Yao, 2012, Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2+ Breast Cancer Growth and Metastasis, Sci. Transl. Med., 4, 130ra148, 10.1126/scitranslmed.3003601

Song, 2005, Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors, Nat. Biotechnol., 23, 709, 10.1038/nbt1101

Kim, 2011, Antibody-mediated delivery of siRNAs for anti-HIV therapy, Methods Mol. Biol., 721, 339, 10.1007/978-1-61779-037-9_21

Kumar, 2008, T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice, Cell, 134, 577, 10.1016/j.cell.2008.06.034

Gump, 2007, TAT transduction: the molecular mechanism and therapeutic prospects, Trends Mol. Med., 13, 443, 10.1016/j.molmed.2007.08.002

Lundberg, 2007, Delivery of short interfering RNA using endosomolytic cell-penetrating peptides, FASEB J., 21, 2664, 10.1096/fj.06-6502com

Sugahara, 2009, Tissue-penetrating delivery of compounds and nanoparticles into tumors, Cancer Cell, 16, 510, 10.1016/j.ccr.2009.10.013

Feron, 2010, Tumor-penetrating peptides: a shift from magic bullets to magic guns, Sci. Transl. Med., 2, 34ps26, 10.1126/scitranslmed.3001174

Dupont, 2011, Penetratin story: an overview, Methods Mol. Biol., 683, 21, 10.1007/978-1-60761-919-2_2

Berry, 2008, Intracellular delivery of nanoparticles via the HIV-1 tat peptide, Nanomedicine (Lond.), 3, 357, 10.2217/17435889.3.3.357

Endoh, 2009, Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape, Adv. Drug Deliv. Rev., 61, 704, 10.1016/j.addr.2009.04.005

Xiong, 2011, Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin, ACS Nano, 5, 5202, 10.1021/nn2013707

Leng, 2005, Highly branched HK peptides are effective carriers of siRNA, J. Gene Med., 7, 977, 10.1002/jgm.748

Zhou, 2010, Aptamer-targeted cell-specific RNA interference, Silence, 1, 4, 10.1186/1758-907X-1-4

Tuerk, 1992, RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase, Proc. Natl. Acad. Sci. USA, 89, 6988, 10.1073/pnas.89.15.6988

Famulok, 1999, Aptamers as tools in molecular biology and immunology, Curr. Top Microbiol. Immunol., 243, 123

Dassie, 2009, Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors, Nat. Biotechnol., 27, 839, 10.1038/nbt.1560

Zhou, 2008, Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy, Mol. Ther., 16, 1481, 10.1038/mt.2008.92

Zhou, 2009, Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells, Nucleic Acids Res., 37, 3094, 10.1093/nar/gkp185

Thiel, 2012, Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers, Nucleic Acids Res., 40, 6319, 10.1093/nar/gks294

McNamara, 2006, Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras, Nat. Biotechnol., 24, 1005, 10.1038/nbt1223

Zhao, 2011, A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma, J. Nanobiotechnology, 9, 2, 10.1186/1477-3155-9-2

Kim, 2010, Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex, Biomaterials, 31, 4592, 10.1016/j.biomaterials.2010.02.030

Bagalkot, 2011, siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing, ACS Nano, 5, 8131, 10.1021/nn202772p

Ye, X., Hemida, M., Zhang, H.M., Hanson, P., Ye, Q., and Yang, D. (2012). Current advances in Phi29 pRNA biology and its application in drug delivery. Wiley Interdiscip. Rev. RNA.

Guo, 2010, The emerging field of RNA nanotechnology, Nat. Nanotechnol., 5, 833, 10.1038/nnano.2010.231

Tarapore, 2011, Application of phi29 motor pRNA for targeted therapeutic delivery of siRNA silencing metallothionein-IIA and survivin in ovarian cancers, Mol. Ther., 19, 386, 10.1038/mt.2010.243

Liu, 2011, Fabrication of stable and RNase-resistant RNA nanoparticles active in gearing the nanomotors for viral DNA packaging, ACS Nano, 5, 237, 10.1021/nn1024658

Zhou, 2011, Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition, Methods, 54, 284, 10.1016/j.ymeth.2010.12.039

Shu, 2011, Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics, Nat. Nanotechnol., 6, 658, 10.1038/nnano.2011.105